D-cycloserine to enhance extinction of cue-elicited craving for alcohol: A translational approach

Translational Psychiatry

Volumn 5, Issue , 2015, Pages e544-

  MacKillop, J ^a,b,c   Few, L R ^d   Stojek, M K ^e   Murphy, C M ^e   Malutinok, S F ^e   Johnson, F T ^e   Hofmann, S G ^f   McGeary, J E ^c,g,h   Swift, R M ^c,f   Monti, P M ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b Homewood Health Centre Guelph   (Canada)

^c BROWN UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of Georgia   (United States)

^f BOSTON UNIVERSITY   (United States)

^g PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CYCLOSERINE; PLACEBO; ANTIMETABOLITE;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL USE DISORDER; ALCOHOL WITHDRAWAL; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; DIZZINESS; DROWSINESS; DRUG INDUCED HEADACHE; FEMALE; FOLLOW UP; HELP SEEKING BEHAVIOR; HUMAN; MALE; MENTAL DISEASE; OUTCOME ASSESSMENT; RASH; SKIN TINGLING; SLURRED SPEECH; TRANSLATIONAL RESEARCH; AGED; ALCOHOL-RELATED DISORDERS; ASSOCIATION; CRAVING; DRUG EFFECTS; MIDDLE AGED; OUTPATIENT; PSYCHOLOGY; REINFORCEMENT; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ALCOHOL-RELATED DISORDERS; ANTIMETABOLITES; CRAVING; CUES; CYCLOSERINE; EXTINCTION, PSYCHOLOGICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; TIME FACTORS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927168248     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.41     Document Type: Article

References (64)

1. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry 2005; 162: 1414-1422.
2. Bigelow GE. An operant behavioral perspective on alcohol abuse and dependence. Heather, N, Peters, TJ, Stockwell, T (eds). International Handbook of Alcohol Dependence and Problems. John Wiley & Sons, Ltd: Chicester, UK, 2001. pp 299-315.
3. Robinson TE, Berridge KC. Review. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3137-3146.
4. Milton AL, Everitt BJ. The persistence of maladaptive memory: addiction, drug memories and anti-relapse treatments. Neurosci Biobehav Rev 2012; 36: 1119-1139.
5. Siegel S, Ramos BMC. Applying laboratory research: drug anticipation and the treatment of drug addiction. Exp Clin Psychopharmacol 2002; 10: 162-183.
6. Carter BL, Tiffany ST. Meta-analysis of cue-reactivity in addiction research. Addiction 1999; 94: 327-340.
7. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacol 2002; 160: 19-29.
8. MacKillop J, Lisman SA. Reactivity to alcohol cues: isolating the role of perceived availability. Exp Clin Psychopharmacol 2005; 13: 229-237.
9. Flannery BA, Poole SA, Gallop RJ, Volpicelli JR. Alcohol craving predicts drinking during treatment: an analysis of three assessment instruments. J Stud Alcohol 2003; 64: 120-126.
10. Ramo DE, Brown SA. Classes of substance abuse relapse situations: a comparison of adolescents and adults. Psychol Addict Behav 2008; 22: 372-379.
11. Tiffany ST, Wray JM. The clinical significance of drug craving. Ann N Y Acad Sci 2012; 1248: 1-17.
12. Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective information. Psychol Bull 1986; 99: 20-35.
13. Foa EB Huppert JB Cahill S. Emotional processing theory: an update. Rothbaum, BO (ed). Pathological Anxiety: Emotional Processing in Etiology and Treatment. Guilford Press: New York, NY, USA, 2006. pp 3-24.
14. Conklin CA, Tiffany ST. Applying extinction research and theory to cue-exposure addiction treatments. Addiction 2002; 97: 155-167.
15. Monti PM MacKillop J. Advances in the treatment of craving for alcohol and tobacco. In: Miller, PM, Kavanagh, DJ (eds). Translation of Addictions Sciences into Practice. Elsevier Press: Amsterdam, The Netherlands, 2007. pp 209-235.
16. Kelley AE. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 2004; 44: 161-179.
17. Peters J, De Vries TJ. Glutamate mechanisms underlying opiate memories. Cold Spring Harb Perspect Med 2012; 2: a012088.
18. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61: 1136-1144.
19. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M et al. Dcycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007; 62: 835-838.
20. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA et al. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 2010; 67: 365-370.
21. Hofmann SG, Meuret AE, Smits JAJ, Simon NM, Pollack MH, Eisenmenger K et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63: 298-304.
22. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63: 544-549.
23. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63: 1118-1126.
24. Hofmann SG, Smits JAJ, Rosenfield D, Simon N, Otto MW, Meuret AE et al. DCycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry 2013; 170: 751-758.
25. Groblewski PA, Lattal KM, Cunningham CL. Effects of D-cycloserine on extinction and reconditioning of ethanol-seeking behavior in mice. Alcohol Clin Exp Res 2009; 33: 772-782.
26. Vengeliene V, Kiefer F, Spanagel R. D-cycloserine facilitates extinction of conditioned alcohol-seeking behaviour in rats. Alcohol Alcohol 2008; 43: 626-629.
27. Myers KM, Carlezon WA. D-cycloserine facilitates extinction of naloxone-induced conditioned place aversion in morphine-dependent rats. Biol Psychiatry 2010; 67: 85-87.
28. Kamboj SK, Massey-Chase R, Rodney L, Das R, Almahdi B, Curran HV et al. Changes in cue reactivity and attentional bias following experimental cue exposure and response prevention: a laboratory study of the effects of D-cycloserine in heavy drinkers. Psychopharmacology (Berl) 2011; 217: 25-37.
29. Hofmann SG, Hüweler R, MacKillop J, Kantak KM. Effects of D-cycloserine on craving to alcohol cues in problem drinkers: preliminary findings. Am J Drug Alcohol Abuse 2012; 38: 101-107.
30. Watson BJ, Wilson S, Griffin L, Kalk NJ, Taylor LG, Munafò MR et al. A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects. Psychopharmacology (Berl) 2011; 216: 121-129.
31. Myers KM, Carlezon WA. D-cycloserine effects on extinction of conditioned responses to drug-related cues. Biol Psychiatry 2012; 71: 947-955.
32. Santa Ana EJ, Rounsaville BJ, Frankforter TL, Nich C, Babuscio T, Poling J et al. DCycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation. Drug Alcohol Depend 2009; 104: 220-227.
33. Price KL, McRae-Clark AL, Saladin ME, Maria MMM-S, DeSantis SM, Back SE et al. Dcycloserine and cocaine cue reactivity: preliminary findings. Am J Drug Alcohol Abuse 2009; 35: 434-438.
34. Rothbaum BO. Critical parameters for D-cycloserine enhancement of cognitivebehaviorial therapy for obsessive-compulsive disorder. Am J Psychiatry 2008; 165: 293-296.
35. Hofmann SG. Enhancing exposure-based therapy from a translational research perspective. Behav Res Ther 2007; 45: 1987-2001.
36. Hood WF, Compton RP, Monahan JB. D-cycloserine: a ligand for the N-methyl-Daspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 1989; 98: 91-95.
37. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 1994; 257: 7-12.
38. Boje KM, Wong G, Skolnick P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res 1993; 603: 207-214.
39. Monti PM, Rohsenow DJ, Rubonis A V, Niaura RS, Sirota AD, Colby SM et al. Alcohol cue reactivity: effects of detoxification and extended exposure. J Stud Alcohol 1993; 54: 235-245.
40. Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM et al. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 1999; 23: 1386-1394.
41. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res 2007; 41: 466-471.
42. Guastella AJ, Lovibond PF, Dadds MR, Mitchell P, Richardson R. A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behav Res Ther 2007; 45: 663-672.
43. MacKillop J, Lisman SA. Effects of a context shift and multiple context extinction on reactivity to alcohol cues. Exp Clin Psychopharmacol 2008; 16: 322-331.
44. Murphy CM, MacKillop J. Mindfulness as a strategy for coping with cue-elicited cravings for alcohol: an experimental examination. Alcohol Clin Exp Res 2014; 38: 1134-1142.
45. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Helping patients who drink too much: a clinician's guide. U.S. Department of Health & Human Services, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism: Bethesda, MD, USA, 2005.
46. Miller WR, Zweben A, DiClemente CC, Rychtarik RG. Motivational Enhancement Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals With Alcohol Abuse and Dependence. National Institute on Alcohol Abuse and Alcoholism Project MATCH Monograph Series (Volume 2). National Institute on Alcohol Abuse and Alcoholism: Rockville, MD, USA, 1999.
47. Del Boca FK, Kranzler HR, Brown J, Korner PF. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res 1996; 20: 1412-1417.
48. Kozlowski LT, Mann RE, Wilkinson DA, Poulos CX. 'Cravings' are ambiguous: ask about urges or desires. Addict Behav 1989; 14: 443-445.
49. Kozlowski LT, Wilkinson DA. Use and misuse of the concept of craving by alcohol, tobacco, and drug researchers. Br J Addict 1987; 82: 31-45.
50. Sayette MA, Shiffman S, Tiffany ST, Niaura RS, Martin CS, Shadel WG. The measurement of drug craving. Addiction 2000; 95(Suppl 2): S189-S210.
51. Klein A, Stasiewicz PR, Koutsky JR, Bradizza CM, Coffey SF. A psychometric evaluation of the Approach and Avoidance of Alcohol Questionnaire (AAAQ) in alcohol dependent outpatients. J Psychopathol Behav Assess 2007; 29: 231-240.
52. Stasiewicz PR, Brandon TH, Bradizza CM. Effects of extinction context and retrieval cues on renewal of alcohol-cue reactivity among alcohol-dependent outpatients. Psychol Addict Behav 2007; 21: 244-248.
53. First, Michael B, Spitzer, Robert L, Miriam G, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). Biometrics Research, New York State Psychiatric Institute: New York, NY, USA, 2002.
54. Sobell LC Sobell MB. Alcohol Timeline Followback (TLFB). In: Handbook of Psychiatric Measures. American Psychiatric Association: Washington, DC, USA, 2000. 477-479.
55. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84: 1353-1357.
56. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods 2008; 40: 879-891.
57. Moyers TB. The Global Rating of Motivational Interviewing Therapists 2004. Downloaded from http://casaa.unm.edu/download/gromit.pdf.
58. Krystal JH, Petrakis IL, Limoncelli D, Nappi SK, Trevisan L, Pittman B et al. Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dependence. Neuropsychopharmacology 2011; 36: 701-710.
59. Santa Ana EJ, Rounsaville BJ, Frankforter TL, Nich C, Babuscio T, Poling J et al. DCycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation. Drug Alcohol Depend 2009; 104: 220-227.
60. Smits JAJ, Rosenfield D, Otto MW, Powers MB, Hofmann SG, Telch MJ et al. Dcycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry 2013; 73: 1054-1058.
61. Smits JAJ, Rosenfield D, Otto MW, Marques L, Davis ML, Meuret AE et al. Dcycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res 2013; 47: 1455-1461.
62. Glautier S, Drummond DC. Alcohol dependence and cue reactivity. J Stud Alcohol 1994; 55: 224-229.
63. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004; 61: 1107-1115.
64. Todd TP, Vurbic D, Bouton ME. Behavioral and neurobiological mechanisms of extinction in Pavlovian and instrumental learning. Neurobiol Learn Mem 2013; 108: 52-64.